Unknown PHASE4 INTERVENTIONAL 1-arm NCT01646450

First-line Treatment With Icotinib in Elder NSCLC EGFR Mutated Patients

An Open Lable, Single Arm, Phase IV Study of Icotinib as First-line Treatment in Elder NSCLC Patients With EGFR Mutation

Sponsor: Betta Pharmaceuticals Co., Ltd.

Conditions Non-Small Cell Lung Cancer

Interventions Icotinib

Updated 7 times since 2017 Last updated: Sep 5, 2015 Started: Jul 31, 2012 Primary completion: Dec 31, 2015 Completion: Apr 30, 2016

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT01646450, this PHASE4 trial focuses on Non-Small Cell Lung Cancer and remains ongoing. Sponsored by Betta Pharmaceuticals Co., Ltd., it has been updated 7 times since 2012, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

7 versions recorded

Sep 2024 — Present [monthly]

Unknown PHASE4
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE4

Status: Unknown Status → Unknown
Jan 2021 — Jul 2024 [monthly]

Unknown Status PHASE4
Feb 2019 — Jan 2021 [monthly]

Unknown Status PHASE4
Jun 2018 — Feb 2019 [monthly]

Unknown Status PHASE4

▶ Show 2 earlier versions

Oct 2017 — Jun 2018 [monthly]

Unknown Status PHASE4

Status: Active Not Recruiting → Unknown Status
Jan 2017 — Oct 2017 [monthly]

Active Not Recruiting PHASE4

First recorded

Jul 2012

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Betta Pharmaceuticals Co., Ltd.

Data source: Betta Pharmaceuticals Co., Ltd.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Shanghai, China